Oriola (ORIOLA.HE) Stock Analysis & AI Equity Report
Oriola (ORIOLA.HE) overview
Oriola (NASDAQ Helsinki: ORIOLA.HE) stock analysis and AI equity research. Oriola shares trade at 0.93 EUR; Valuatum rates ORIOLA.HE BUY with a 1.60 EUR 12-month price target (+71.9% vs the current share price). This Medical - Distribution equity research report covers Oriola's valuation, segment-value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
52-week range 0.87 EUR – 1.26 EUR · 1-year change -10.3% · 3-year change -23.8%.
Executive summary
Oriola Oyj (ORIOLA.HE, NASDAQ Helsinki) is a Finland-based health and wellbeing company linking pharmaceutical manufacturers with the healthcare system in Finland and Sweden; in this Valuatum equity research report dated 7 July 2026 we rate the stock BUY with a 12-month target price of 1.60 EUR against a current price of 0.93 EUR, implying +71.9% upside. Market capitalisation is EUR 173 m and enterprise value is EUR 281 m.
The core valuation tension is a market that prices Oriola on its poor statutory cash conversion and ERP execution risk rather than its infrastructure monopoly and adjusted earnings power. The Distribution segment generates EUR 32.6 million of FY25 adjusted EBITDA against just EUR 128.1 million of allocated enterprise value, a 3.9x multiple well below Oriola's own normalized 5.5x EV/EBITDA average, while the company value map carries the whole group at only EUR 138 million of enterprise value and assigns the 50% Kronans Apotek retail pharmacy joint venture — Sweden's third-largest chain with an estimated book value of around EUR 206 million — an EV of zero. On a reverse-valuation basis the market's assumptions look overly pessimistic: applying a conservative 8.0x multiple to the EUR 35.1 million of adjusted EBITDA would support roughly EUR 280 million of operating enterprise value against the current EUR 138 million, implying the market simply does not believe the adjusted EBITDA is real. The scenario base case implies EUR 1.34 per share (+44.3%), the bull case EUR 2.29 (+145.7%) on Agent Net Sales operating leverage plus realization of the Kronans Apotek asset, and even the bear case of a working capital failure with dilutive emergency financing implies EUR 0.94 (+0.8%). The key condition is keeping the estimated EUR -151 million 2026e operating cash outflow within the EUR 70 million unused revolver.
Investment thesis — three reasons
Distribution generates EUR 32.6m adjusted EBITDA against just EUR 128.1m allocated EV, a 3.9x multiple well below Oriola's own normalized 5.5x average, leaving room for re-rating.
Segment value analysis — enterprise-value allocation
The segment value analysis decomposes Oriola's enterprise value into the distinct businesses and options the market is paying for. The allocation across each segment is shown below; the full segment economics are in the report.
Regulated profit engine valued as a distressed asset rather than a stable infrastructure monopoly: EUR 128.1 million of allocated EV against EUR 32.6 million of adjusted EBITDA is a 3.9x multiple, a heavy penalty for years of bungled ERP rollouts and working capital volatility. Oriola and its main competitor Tamro control the Nordic single-channel duopoly with a ~42-46% Nordic share; from 2026 the IFRS 15 shift from principal to agent reporting means gross 'Invoicing' of over EUR 4 billion while Net Sales fall to an estimated EUR 210 million, revealing a ~20% margin infrastructure toll road.
Reverse valuation
The reverse valuation tests whether the pessimism embedded in Oriola's EUR 138 million allocated enterprise value is coherent, with the 2026 working capital event and the finalization of the Järvenpää ERP go-live as the swing factors. Oriola holds a net cash position of EUR 74 million pre-2026 reset, but consensus estimates forecast a EUR -151 million operating cash flow in 2026 that would push the company into EUR 109 million of net debt; the Base case assumes standard EBITDA normalization but no JV sale, the Bull case assumes immediate operating leverage on Agent Net Sales and realization of the Kronans Apotek asset, and the Bear case assumes a working capital failure that necessitates highly dilutive emergency financing.
Oriola financial statements & estimates
All figures in EUR millions unless noted; per-share data in EUR.
Unlock the full Oriola report
The full PDF adds the complete reverse-valuation scenario model, segment financial statements and estimates, the full risk & catalyst analysis, and the institutional one-page snapshot. Instant download for €20.00.
Oriola (ORIOLA.HE) stock — frequently asked questions
Is Oriola (ORIOLA.HE) a buy or a sell?
Valuatum's latest AI equity report rates Oriola (ORIOLA.HE) BUY, with a 12-month price target of 1.60 EUR versus a 0.93 EUR share price (+71.9%). The full report explains the rationale behind the rating.
What is the Oriola (ORIOLA.HE) share price target?
The current Valuatum 12-month price target for Oriola is 1.60 EUR, implying +71.9% versus the current share price. Unlock the report for the valuation behind the target.
How is Oriola (ORIOLA.HE) valued?
The Oriola AI equity report values the company using segment-value analysis and a reverse valuation (a DCF-style framework), with segment financial estimates, key ratios, risks and catalysts. Buy the report to read the full valuation.
Where can I get the Oriola (ORIOLA.HE) equity research report?
Buy the Oriola (ORIOLA.HE) AI equity report PDF on this page for instant download, or generate a fresh report for any listed company.
Sources & methodology
- Primary data: Valuatum Equity Research, Oriola report dated 7 July 2026 (company value map; FY25 Distribution adjusted EBITDA EUR 32.6m, current quote EUR 0.931).
- Consensus estimates: consensus forecast of a EUR -151 million operating cash flow in 2026 used for the cash-bridge analysis.
- Market data: Ticker ORIOLA.HE current price 0.93 EUR as of 7 July 2026; FY25 group net sales EUR 1,906m; 2026e group EBITDA EUR 44m (analyst-generated estimate).
This report was generated using Valuatum's AI equity research framework — a structured enterprise-value and segment value methodology built on 25+ years of professional equity research practice. See the methodology for the full approach.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.